Retarding progression of chronic renal disease: the neglected issue of residual proteinuria - PubMed (original) (raw)
Clinical Trial
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria
Piero Ruggenenti et al. Kidney Int. 2003 Jun.
Free article
Abstract
Background: Findings that early changes in proteinuria independently predict long-term glomular filtration rate (GFR) decline (Delta GFR) would highlight proteinuria as a major determinant of progression in chronic renal disease.
Methods: We investigated whether percent changes (3 months vs. baseline) in proteinuria (adjusted for concomitant changes in GFR) and residual proteinuria at 3 months, predicted Delta GFR [over a median (IQ range) follow up of 31.3 (24.5 to 50.3) months] in 273 patients with proteinuric chronic nephropathies enrolled in the Ramipril Efficacy In Nephropathy (REIN) study.
Results: Short-term changes and residual proteinuria (r = -0.23, P = 0.0001 for both) significantly correlated with Delta GFR and, at multivariate analyses, independently predicted Delta GFR (beta = -0.23, P = 0.0002; beta = -0.21, P = 0.0004, respectively). For comparable levels of residual proteinuria, patients with greater short-term reduction had slower Delta GFR (-0.28 +/- 0.04 mL/min/1.73 m2/ vs. -0.53 +/- 0.07 mL/min/1.73 m2/month, P = 0.04). On ramipril and conventional treatment, specular short-term changes in proteinuria (-18.2 +/- 3.5% vs. 24.2 +/- 6.7%, P < 0.0001, respectively) were associated with significantly different Delta GFRs. However, similar changes in proteinuria resulted in a difference in Delta GFR (ramipril, 0.39 +/- 0.07 mL/min/1.73 m2/month; conventional therapy, 0.74 +/- 0.11 mL/min/1.73 m2/month; P < 0.01) that was sevenfold higher (0.35 vs. 0.05 mL/min/1.73 m2/month) in patients with basal proteinuria > or =3 g/24 hours as compared to those with basal proteinuria 1 to 3 g/24 hours (ramipril, 0.25 +/- 0.06 mL/min/1.73 m2/month; conventional therapy, 0.30 +/- 0.07 mL/min/1.73 m2/month; P = NS).
Conclusion: Regardless of blood pressure control and treatment randomization, short-term changes in proteinuria and residual proteinuria reliably predict long-term disease progression. Reducing proteinuria is renoprotective, particularly in nephrotic patients. As for arterial hypertension, proteinuria should be a specific target for renoprotective treatment.
Similar articles
- Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Ruggenenti P, et al. Kidney Int. 1998 May;53(5):1209-16. doi: 10.1046/j.1523-1755.1998.00874.x. Kidney Int. 1998. PMID: 9573535 Clinical Trial. - Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G. Ruggenenti P, et al. Kidney Int Suppl. 1997 Dec;63:S54-7. Kidney Int Suppl. 1997. PMID: 9407422 Clinical Trial. - Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.
Chiurchiu C, Remuzzi G, Ruggenenti P. Chiurchiu C, et al. J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S58-63. doi: 10.1681/asn.2004110968. J Am Soc Nephrol. 2005. PMID: 15938036 Review.
Cited by
- Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: a retrospective single center study.
Jørgensen HS, Winther S, Povlsen JV, Ivarsen P. Jørgensen HS, et al. BMC Nephrol. 2012 Sep 7;13:102. doi: 10.1186/1471-2369-13-102. BMC Nephrol. 2012. PMID: 22958603 Free PMC article. - Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.
Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL. Boesby L, et al. PLoS One. 2011;6(11):e26904. doi: 10.1371/journal.pone.0026904. Epub 2011 Nov 4. PLoS One. 2011. PMID: 22073219 Free PMC article. Clinical Trial. - Proteinuria: Is the ONTARGET renal substudy actually off target?
Ruggenenti P, Remuzzi G. Ruggenenti P, et al. Nat Rev Nephrol. 2009 Aug;5(8):436-7. doi: 10.1038/nrneph.2009.109. Nat Rev Nephrol. 2009. PMID: 19639016 No abstract available. - Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease.
Morales E, Caro J, Gutierrez E, Sevillano A, Auñón P, Fernandez C, Praga M. Morales E, et al. Kidney Int. 2015 Dec;88(6):1434-1441. doi: 10.1038/ki.2015.249. Epub 2015 Aug 26. Kidney Int. 2015. PMID: 26308670 - Achieving remission of proteinuria in childhood CKD.
Ruggenenti P, Cravedi P, Chianca A, Caruso M, Remuzzi G. Ruggenenti P, et al. Pediatr Nephrol. 2017 Feb;32(2):321-330. doi: 10.1007/s00467-016-3495-1. Epub 2016 Oct 4. Pediatr Nephrol. 2017. PMID: 27704256 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous